Crescent Biopharma
CBIO
13.44
-0.05
-0.34%
Crescent Biopharma
US · CBIO
#3749 by market cap
13.44
-0.05
-0.34%
Live - 5344 symbols - heartbeat 397s ago
· 2026-10-08 09:54
After-hours
13.49
0.00%
Overnight
13.16
-2.45%
- Market cap
- 499.39M
- P/E (TTM)i
- -96.03
- P/Bi
- 3.14
- EPSi
- -12.81
- Div yieldi
- 0.00%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on CBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.99, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Margins
- Operating margin
- -1,407.52%
- Net margin
- -1,419.61%
Key ratios & quality
- Altman Z-Scorei
- 5.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | 10.84M |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 25.39M |
| Research & development | -- | 138.09M |
| Operating profit | -- | -152.63M |
| Pretax profit | -- | -151.94M |
| Tax | -- | 2.00M |
| Net profit | -- | -153.94M |
| Basic EPS | -- | -13 |
| Diluted EPS | -- | -12.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | -- | -- | 1.04M | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.60M | 8.95M | 5.54M | 7.31M | 7.87M | 8.74M |
| Research & development | 10.63M | 12.08M | 20.35M | 95.03M | 17.90M | 19.39M |
| Operating profit | -14.22M | -21.03M | -25.89M | -91.49M | -24.73M | -26.36M |
| Pretax profit | -15.15M | -21.79M | -24.61M | -90.40M | -23.28M | -24.84M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -15.15M | -21.79M | -24.61M | -92.40M | -23.28M | -24.84M |
| Basic EPS | -1 | -5 | -1 | -4 | -1 | -1 |
| Diluted EPS | -0.78 | -4.93 | -1.27 | -4.01 | -0.70 | -0.74 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 34.80M | 236.66M |
| Cash & ST investments | 34.77M | 213.19M |
| Inventory | -- | -- |
| Total assets | 35.62M | 240.29M |
| Total current liabilities | 9.61M | 36.07M |
| Short-term debt | -- | 435.00K |
| Long-term debt | 37.48M | -- |
| Total liabilities | 51,096,000.00 | 37,281,000.00 |
| Total equity | -15.48M | 203.01M |
| Retained earnings | -17.87M | -171.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 154.23M | 134.56M | 236.66M | 195.56M | 179.01M |
| Cash & ST investments | -- | 152.65M | 133.27M | 213.19M | 189.16M | 171.59M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 157.43M | 138.27M | 240.29M | 199.13M | 182.76M |
| Total current liabilities | -- | 16.75M | 20.30M | 36.07M | 14.19M | 18.54M |
| Short-term debt | -- | 211.00K | 417.00K | 435.00K | 453.00K | 471.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | 18,179,000.00 | 21,628,000.00 | 37,281,000.00 | 15,283,000.00 | 19,503,000.00 |
| Total equity | -- | 139.25M | 116.64M | 203.01M | 183.85M | 163.26M |
| Retained earnings | -- | -54.81M | -79.41M | -171.81M | -195.09M | -219.93M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -71.53M |
| Depreciation & amortization | -- | 84.00K |
| Free cash flow | -- | -144.45M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | 321.71M |
| Ending cash balance | -- | 213.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -10.85M | -16.40M | -17.54M | -26.74M | -8.94M | -19.46M |
| Depreciation & amortization | 0 | 2.00K | 28.00K | 54.00K | 64.00K | 66.00K |
| Free cash flow | -10.85M | -16.54M | -18.13M | -98.93M | -17.08M | -19.48M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -1.08M | 178.68M | -- | -- |
| Ending cash balance | 22.43M | 152.75M | 133.37M | 213.30M | 189.27M | 171.70M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -167.75 |
| ROA %i | -- | -111.59 |
| ROIC %i | -- | -138.47 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -1,381.01 |
| FCF / sales %i | -- | -- |
| Current ratioi | 3.62 | 6.56 |
| Quick ratioi | 3.62 | 6.41 |
| Debt / assetsi | 105.24 | 0.68 |
| LT debt / equityi | -- | 0.61 |
| Interest coveragei | -- | -68.54 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -167.75 | -90.12 | -112.14 |
| ROA %i | -- | -- | -- | -111.59 | -81.39 | -97.08 |
| ROIC %i | -- | -- | -- | -138.47 | -91.04 | -114.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -1,381.01 | -1,338.08 | -1,372.75 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 9.21 | 6.63 | 6.56 | 13.78 | 9.66 |
| Quick ratioi | -- | 9.12 | 6.56 | 6.41 | 13.33 | 9.26 |
| Debt / assetsi | -- | 1.04 | 1.26 | 0.68 | 0.77 | 0.79 |
| LT debt / equityi | -- | 1.06 | 1.18 | 0.61 | 0.61 | 0.61 |
| Interest coveragei | -- | -- | -- | -68.54 | -148.19 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of its research programs, CR-001, CR-002, and CR-003100.00%
Quote time 2026-10-08 09:54:40 · For reference only, not investment advice and not tailored to your situation.